FDA Approves Self-Administered Satralizumab for Thyroid Eye Disease
The FDA has approved satralizumab (Enspryng) for adults with thyroid eye disease, making it the first self-administered subcutaneous option for the condition, according to Roche. The drug is a monoclonal antibody that blocks interleukin-6 receptors. In the phase III SatraGO program, one trial missed its primary endpoint at 24 weeks, but another showed better reductions in eye bulging and double vision than placebo.
Satralizumab is a humanized monoclonal antibody that targets interleukin-6 receptors, blocking a signaling route tied to inflammation. It was approved for adults with thyroid eye disease, also called Graves' ophthalmopathy, a rare autoimmune inflammatory condition often seen with hyperthyroidism. The FDA decision rests on two phase III trials, SatraGO-1 and SatraGO-2, involving 258 participants in 19 countries; SatraGO-1 did not meet its week-24 primary endpoint.
In SatraGO-2, more satralizumab-treated patients with active disease achieved at least 2 mm less proptosis and reduced diplopia than those on placebo. Similar findings appeared in the broader group, which included active and chronic disease. The drug is already approved for neuromyelitis optica spectrum disorder, and its safety profile there was consistent with these trials.
For adults with thyroid eye disease, a self-administered subcutaneous option may reduce reliance on infusion centers and travel, potentially easing treatment burden for patients and caregivers. It could broaden choices alongside existing intravenous therapies, though eligibility, screening requirements, and monitoring needs may shape real-world use. Because TED can affect vision, appearance, and daily function, easier access to effective treatment could improve quality of life for some patients, while clinicians may weigh benefits against safety considerations and individual disease status.